Relay Therapeutics appoints Claire Mazumdar to board; Jami Ruben resigns

Relay Therapeutics, Inc.

Jami Ruben resigned as Class III director and Audit Committee member effective June 8, 2025; no dispute or disagreement.
Claire Mazumdar, Ph.D., appointed as Class III director and Audit Committee chair effective June 9, 2025.
Dr. Mazumdar is founding CEO of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company.
She received an initial option to purchase 421,241 shares at $3.36/share, vesting monthly over three years.
Board determined Dr. Mazumdar is independent under Nasdaq listing standards.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Claire Mazumdar

Class III Director

RLAY · Relay Therapeutics, Inc.

Effective: 2025-06-09
Filed: Jun 11, 2025 23:59 UTC

On June 9, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Claire Mazumdar, Ph.D., MBA as a member of the Board, effective as of June 9, 2025.

Source: SEC EDGAR

accession 0001193125-25-139146

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.